1 / 5

Carfilzomib Multiple Myeloma Medication-converted

Carfilzomib injection is used to treat relapsed or refractory multiple myeloma in patients who have received 1 or more previous treatments.

Chitransha
Download Presentation

Carfilzomib Multiple Myeloma Medication-converted

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carfilzomib: Multiple Myeloma Medication Carfilzomib is a new class of drugs called proteasome inhibitors. These proteasome inhibitors basically work by blocking the activity of enzyme complexes called proteasomes. Carfilzomib is aimed to treat adult patients with multiple myeloma (MM) who have had at least one previous treatment for this disease. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

  2. Effects of Carfilzomib Low Amount Of Magnesium In The Blood Low Amount Of Potassium In The Blood Anemia Decreased Blood Platelets Low Levels Of White Blood Cells Low Levels Of A Type Of White Blood Cell Called Neutrophils • • • • • •

  3. Precautions 1. Cardiac Arrest: Death due to cardiac arrest has occurred within a day of KYPROLIS administration. New onset or worsening of pre-existing congestive heart failure with decreased left ventricular function or myocardial ischemia have occurred following administration of KYPROLIS. 2. Pulmonary Complications: Dyspnea was reported in 35% of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade 5) was reported. 3. Infusion Reactions- Infusion reactions were characterized by a spectrum of systemic symptoms including fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. 4. Tumor Lysis Syndrome: Tumor lysis syndrome (TLS) occurred following KYPROLIS administration in < 1% of patients. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS.

  4. How does Carfilzomib work? When Carfilzomib inhibits proteasomes, the normal balance within a cell is disrupted. Such kind of disruption results in a number of effects. Cancerous cells are quite sensitive to these effects in comparison to the normal cells, so in this way cancerous cells die while normal cells are able to recover. Availability In India, there are many pharmaceutical company but The Indian Pharma is the best pharma company for providing Carfilzomib injection. This is one of the top-certified pharmaceutical organization, supplying quality medicines all over the world.

More Related